All In Biotech

NDA 020457 · Cheplapharm

Etopophos Preservative Free

Etoposide Phosphate · Injection

Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

May 17, 1996

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,914

435 Phase 3, 235 recruiting

FAERS reports

1,635

1,491 serious, 296 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 31, 2026.

ETOPOPHOS is a topoisomerase inhibitor indicated for the treatment of patients with: Refractory testicular tumors, in combination with other chemotherapeutic drugs. ( 1.1 ) Small cell lung cancer, in combination with cisplatin, as first-line treatment. ( 1.2 ) 1.1 Refractory Testicular Tumors ETOPOPHOS is indicated, in combination with other chemotherapeutic drugs, for treatment of patients with refractory testicular tumors. 1.2 Small Cell Lung Cancer ETOPOPHOS is indicated, in combination with cisplatin, for first-line treatment of patients with small cell lung cancer.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 17, 1996 Original approval · Type 2 - New Active Ingredient
1 products under this application
  • ETOPOPHOS PRESERVATIVE FREE · ETOPOSIDE PHOSPHATE EQ 100MG BASE/VIAL · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Etoposide" as an intervention, any sponsor and status, largest first.

All 1,914 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use200
  • disease progression163
  • product use in unapproved indication93
  • acute kidney injury83
  • thrombocytopenia82
  • febrile neutropenia72
  • pyrexia71
  • drug ineffective68
  • malignant neoplasm progression68
  • neutropenia61
  • product storage error61
  • anaemia59

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20046
20054
200610
200711
20103
201219
201357
201452
201568
2016126
201786
2018182
2019164
202095
2021107
2022151
2023188
2024138
2025102
202666

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,076 on PubMed

Sponsor: Cheplapharm

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.